SUMITOMO PHARMA AMERICA ANNOUNCES ENZOMENIB (DSP-5336) RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF R/R KMT2A-REARRANGED ACUTE LEUKEMIA

Reuters · 1d ago

Please log in to view news